FDA warning letters detail issues for manufacturing sites in the US and India
The FDA this week released new warning letters for drug manufacturers in the US and India following the discovery of several quality issues.
One warning letter was handed to Fort Worth, TX-based Sovereign Pharmaceuticals last month which detailed that the site had “failed to validate the manufacturing process” for an undisclosed tablet, as some of the active ingredients were out-of-specification.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.